In central retinal vein occlusion (CRVO) a blood clot blocks the venous outflow of the entire
retinal circulation. This leads to retinal and vitreous hemorrhages, retinal edema and
neovascularization. The development of a microneedle and surgical stabilizer made it possible
to perform a prolonged (10 minutes) retinal vein cannulation with infusion of Ocriplasmin.
Ocriplasmin has the advantage over tissue Plasminogen Activator (tPA) that it already is an
active enzyme and a strong fibrinolyticum. This study aims to investigate the feasibility and
safety of local intravenous Ocriplasmin for CRVO.